#USA #Chicago #Cancer Research #Bio-Techne #AACR 2025

Bio-Techne Set to Showcase Innovations in Cancer Research at the 2025 AACR Annual Meeting

Bio-Techne Corporation (NASDAQ: TECH) is gearing up for a significant presence at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, taking place from April 25 to 30 at the McCormick Place Convention Center. This prestigious event, known for convening the world's leading cancer experts, provides a platform for Bio-Techne to demonstrate its latest advancements in cancer research tools designed to enhance the oncology landscape.

At the meeting, located at booth #3049, Bio-Techne will present an array of innovative solutions that support researchers in various stages of cancer research such as early discovery, translational applications, and the development of cell and gene therapies. The showcased portfolio includes high-performance proteins, antibodies, small molecules, cell culture reagents, immunoassays, automated proteomic analysis platforms, and spatial multiomic solutions, each engineered to accelerate advancements in oncology research and facilitate the development of next-generation diagnostic tools.

A highlight of their presentation will be Advanced Cell Diagnostics (ACD), a Bio-Techne brand, which will unveil its full suite of spatial multiomic research solutions, where leading-edge workflows are coupled with the versatile RNAscope™ spatial portfolio. Furthermore, the company will also present scientific posters and co-host an evening reception on April 27 with partners Leica Biosystems and Indica Labs to delve deeper into multiomic detection capabilities.

Additionally, attendees can visit booth #3249, where Lunaphore, another entity within the Bio-Techne family, will share its comprehensive end-to-end spatial biology solutions. Lunaphore has recently advanced its portfolio by introducing a fully-automated multiomics application for fixed-frozen tissues. This innovative platform aims to provide enhanced tools for researchers looking to navigate the increasingly complex world of spatial biology. Furthermore, an exclusive dinner reception on April 28 will serve as a networking opportunity for leaders within the spatial biology community, where specific discussions around emerging technologies like the HORIZON™ image analysis software will take place.

As stated by Kim Kelderman, CEO of Bio-Techne, “The pace of cancer research is rapidly evolving, and it is crucial for us to equip researchers with the necessary tools to facilitate their discoveries and drive innovation.” This commitment underscores Bio-Techne's role in advancing not only fundamental science but also its application within precision medicine and the development of next-generation cancer therapies. The AACR meeting presents a unique opportunity for Bio-Techne to connect with industry leaders, showcasing how its solutions can help reshape the landscape of cancer research and ultimately contribute to the fight against cancer.

Expected Presentations and Discussions

Bio-Techne has a series of presentations lined up during the conference, which will include:

• - Protein Quantitation for Characterization of Potential Cancer Therapeutics on April 29. This session will focus on insights gained during both early discovery and in translational studies.
• - Evaluation of IDH1, EGFR, IGF1R, and Ki67 Biomarkers in Glioblastoma, utilizing the Lunaphore COMET™ Platform on April 28, aimed at enhancing understanding in glioblastoma.
• - Discussions around Multiomic Co-Detection and the insights it can provide concerning the tumor microenvironment in bladder cancer are also scheduled for April 28. Presenters will reveal findings related to the interactions between PD1 and PDL1.
• - Moreover, various sessions will draw attention to advanced techniques like high-throughput spatial multiomics, emphasizing immune cell phenotyping functionality, with talks spanning various days of the conference.

Conclusion

Bio-Techne's inclusive participation at the AACR Annual Meeting signifies its enduring commitment to progressing cancer research. Through its innovative offerings and expertise, the company aims to make a substantial impact on the future of oncology research and therapy development. The presence of Bio-Techne at this distinguished conference accentuates their role as a pivotal player in the cancer research community, advocating scientific collaboration and innovation.

For more details about Bio-Techne's appearances and presentations, attendees can visit their official event page.